For information about COVID-19, including symptoms and prevention, please read our COVID-19 patient guide. If you need to see your provider, please contact us to see if a Video Visit is right for you. Please also consider supporting Weill Cornell Medicine’s efforts against the pandemic.
Roy M. Gulick, M.D., M.P.H., ChiefMajor laboratory research projects in the ID Division investigate antibiotic and antifungal drug development, bacterial pathogenesis and drug resistance, bioterrorism agents, influenza, leishmaniasis, malaria and tuberculosis. Major clinical research projects investigate bacterial infections and drug resistance, healthcare-associated infections, hepatitis B and C, HIV/AIDS, human papillomavirus, and transplantation/oncology ID.
The clinical programs of the ID Division serve both outpatients and inpatients from the greater New York City area. Weill Cornell ID Associates includes the ID faculty and fellows outpatient practice and the Travel Medicine service, serving about 3,500 travelers a year. More than 1,000 inpatient consultations per year are seen at NYPH/Weill Cornell Medical Center, a large 867-bed tertiary care hospital, and our affiliated hospital, the Hospital for Special Surgery. The HIV/AIDS Program provides care to over 2,500 HIV-infected persons in the Center for Special Studies, in addition to conducting translational and clinical research in the HIV Clinical Trials Unit. Other major clinical programs in the ID Division are the Transplantation/Oncology ID Service and the Hospital Epidemiology/Infection Control Program.
The Center for Global Health coordinates the ID Division's international network of research, clinical and training programs, including those in Brazil, Haiti, India, and Tanzania, with faculty at each site. Research interests include HIV/AIDS, HTLV-1, leishmaniasis, leprosy, malaria, schistosomiasis, and tuberculosis.
Please refer to the 
Infectious Disease Division Brochure for additional detailed information.
